Superiority of pulmonary administration of mepenzolate bromide over other routes as treatment for chronic obstructive pulmonary disease

作者：Tanaka Ken Ichiro; Kurotsu Shota; Asano Teita; Yamakawa Naoki; Kobayashi Daisuke; Yamashita Yasunobu; Yamazaki Hiroshi; Ishihara Tomoaki; Watanabe Hiroshi; Maruyama Toru; Suzuki Hidekazu; Mizushima Tohru^*

来源：Scientific Reports, 2014, 4(1): 4510.

DOI：10.1038/srep04510

We recently proposed that mepenzolate bromide (mepenzolate) would be therapeutically effective against chronic obstructive pulmonary disease (COPD) due to its both anti-inflammatory and bronchodilatory activities. In this study, we examined the benefits and adverse effects associated with different routes of mepenzolate administration in mice. Oral administration of mepenzolate caused not only bronchodilation but also decreased the severity of elastase-induced pulmonary emphysema; however, compared with the intratracheal route of administration, about 5000 times higher dose was required to achieve this effect. Intravenously or intrarectally administered mepenzolate also showed these pharmacological effects. The intratracheal route of mepenzolate administration, but not other routes, resulted in protective effects against elastase-induced pulmonary damage and bronchodilation at a much lower dose than that which affected defecation and heart rate. These results suggest that the pulmonary route of mepenzolate administration may be superior to other routes (oral, intravenous or intrarectal) to treat COPD patients.

• 出版日期2014-3-28